
all_success_response = '{"data": [{"Recommendation": "#1: Monitor glucose, HbA1c, blood pressure, body weight, lipid ' \
                       'profile, and renal and liver function every 3 months.  #2: Consider screening patients with ' \
                       'type 1 diabetes for autoimmune thyroid disease and celiac disease soon after diagnosis.  ' \
                       '#3: In people with a history of cognitive impairment/dementia, intensive glucose control ' \
                       'cannot be expected to remediate deficits. Treatment should be tailored to avoid significant ' \
                       'hypoglycemia.  #4: In men with diabetes who have symptoms or signs of hypogonadism such as ' \
                       'decreased sexual desire (libido) or activity, or erectile dysfunction, consider screening with ' \
                       'a morning serum testosterone level.  #5: Screen for anxiety, depression, and disordered eating. ' \
                       'Annually screen people who are prescribed atypical antipsychotic medications for prediabetes ' \
                       'or diabetes.  #6: Annual dilated and comprehensive eye examination.","Optional/applicable ' \
                       'conditions": "Diabetes","References": "American Diabetes Association"}, {"Recommendation": ' \
                       '"American Diabetes Association recommends a hemoglobin A1c level of less than 7.0%, preprandial ' \
                       'glucose values of 70 to 130 mg/dL (3.9-7.2 mmol/L), and 1- to 2-hour postprandial glucose values ' \
                       'of less than 180 mg/dL (10 mmol/L). They also go on to recommend, Less stringent A1C goals ' \
                       '(such as <8%) may be appropriate for patients with a history of severe hypoglycemia, limited ' \
                       'life expectancy, advanced microvascular or macrovascular complications, extensive comorbid ' \
                       'conditions, or long-standing diabetes in whom the goal is difficult to achieve. And the ' \
                       'American College of Physicians recommends less intensive glucose control in most cases of ' \
                       'type 2 diabetes, saying that targeting A1c levels below 7% may increase risk for death, ' \
                       'weight gain, hypoglycemia, and other adverse effects.","Optional/applicable conditions": ' \
                       '"Diabetes","References": "1. American Diabetes Association Diabetes Care 2018 Jan; ' \
                       '41(Supplement 1).  2. Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; ' \
                       'Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c Targets ' \
                       'for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes ' \
                       'Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern ' \
                       'Med. 2018. PMID: 29507945 doi:10.7326/M17-0939"},{"Recommendation": "For BMI greater than or ' \
                       'equal to 35 with obesity-related conditions (diabetes, hypertension, sleep apnea, fatty liver, ' \
                       'cholesterol problems, GI disorders, heart disease), consider bariatric surgery, such as ' \
                       'laparoscopic adjustable gastric banding or sleeve gastrectomy.","Optional/applicable conditions": ' \
                       '"Diabetes, Overweight or Obesity, Liver disease, Chronic heart disease, Chronic lung disease, ' \
                       'Hypertension","References": "Jensen MD, Ryan DH, Apovian CM, et al; American College of ' \
                       'Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society."},' \
                       '{"Recommendation": "For BMI greater than or equal to 27 with obesity-related conditions (diabetes, ' \
                       'hypertension, sleep apnea, fatty liver, cholesterol problems, GI disorders, heart disease), or ' \
                       'BMI of 30+ without those conditions, can consider pharmacologic treatment with Orlistat or ' \
                       'Lorcaserin.","Optional/applicable conditions": "Diabetes, Overweight or Obesity, Liver disease, ' \
                       'Chronic heart disease, Chronic lung disease, Hypertension","References": "Jensen MD, Ryan DH, ' \
                       'Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on ' \
                       'Practice Guidelines; Obesity Society."},{"Recommendation": "In very high-risk ASCVD patients, ' \
                       'it is reasonable to add ezetimibe to maximally tolerated statin therapy when the LDL level ' \
                       'remains ≥70 mg/dL (≥1.8 mmol/L). In patients at very high risk whose LDL level remains ≥70 ' \
                       'mg/dL (≥1.8 mmol/L) on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 ' \
                       'inhibitor is reasonable. Repeat lipid measurement 4 to 12 weeks after statin initiation or ' \
                       'dose adjustment, repeated every 3 to 12 months as needed.","Optional/applicable conditions": ' \
                       '"Congestive Heart Failure, Chronic heart disease","References": "American College of ' \
                       'Cardiology/AHA, 2018 Guideline on the Management of Blood Cholesterol"}],"meta": {"status": ' \
                       '"success", "totalResults": 5,"path": "https://getguidelines.com/all"}}'

vac_success_response = '{}'
